Search Results
Jun 01, 2026, 16:00 ET Novavax to Participate in 2026 Jefferies Global Healthcare Conference
GAITHERSBURG, Md., June 1, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will participate in the 2026 Jefferies Global Healthcare Conference.
More news about: Novavax, Inc.
May 07, 2026, 16:00 ET Novavax to Participate in BofA Securities 2026 Health Care Conference
GAITHERSBURG, Md., May 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference.
More news about: Novavax, Inc.
May 06, 2026, 08:00 ET Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
GAITHERSBURG, Md., May 6, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2026."Novavax continued to make significant
More news about: Novavax, Inc.
Apr 29, 2026, 16:00 ET Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
GAITHERSBURG, Md., April 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, May
More news about: Novavax, Inc.
Mar 30, 2026, 08:00 ET Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
pipeline GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now
More news about: Novavax, Inc.
Feb 26, 2026, 16:30 ET Novavax to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that it will participate in the following upcoming investor conferences:
More news about: Novavax, Inc.
Feb 26, 2026, 08:00 ET Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025."In 2025, we made significant
More news about: Novavax, Inc.
Feb 19, 2026, 08:00 ET Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on
More news about: Novavax, Inc.
Jan 20, 2026, 07:15 ET Novavax Announces Entering into a License Agreement with Pfizer
royaltiesGAITHERSBURG, Md., Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under the terms of the agreement, Pfizer will obtain
More news about: Novavax, Inc.
Jan 07, 2026, 08:00 ET Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference.
More news about: Novavax, Inc.
Nov 12, 2025, 08:00 ET Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md., Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference:
More news about: Novavax, Inc.
Nov 06, 2025, 08:00 ET Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
GAITHERSBURG, Md., Nov. 6, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2025. "We have continued
More news about: Novavax, Inc.
Nov 04, 2025, 07:00 ET Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
GAITHERSBURG, Md., Nov. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™ to Sanofi, enabling Sanofi to take full responsibility
More news about: Novavax, Inc.
Oct 30, 2025, 08:00 ET Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
GAITHERSBURG, Md., Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November
More news about: Novavax, Inc.
Oct 22, 2025, 07:00 ET Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
GAITHERSBURG, Md., Oct. 22, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has further executed against its planned transformation into a lean, agile operating model by signing definitive agreements
More news about: Novavax, Inc.
Oct 07, 2025, 07:00 ET Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
GAITHERSBURG, Md., Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European Union (EU) enabling Sanofi
More news about: Novavax, Inc.
Sep 30, 2025, 09:01 ET Novavax Announces Progress on Sanofi Agreement
GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its
More news about: Novavax, Inc.
Sep 04, 2025, 08:00 ET Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
GAITHERSBURG, Md., Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's COVID-19 vaccine Nuvaxovid® Intramuscular
More news about: Novavax, Inc.
Sep 03, 2025, 08:00 ET Novavax to Participate in the Cantor Global Healthcare Conference
GAITHERSBURG, Md., Sept. 3, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference:
More news about: Novavax, Inc.
Aug 27, 2025, 15:07 ET Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
GAITHERSBURG, Md., Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™ 2025-2026 Formula for the prevention of COVID-19 in
More news about: Novavax, Inc.
Aug 21, 2025, 07:43 ET Novavax Announces Convertible Debt Refinancing
GAITHERSBURG, Md., Aug. 21, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has entered into privately negotiated agreements with certain of the holders of its existing 5.00% Convertible Senior Notes
More news about: Novavax, Inc.
Aug 06, 2025, 08:00 ET Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
GAITHERSBURG, Md., Aug. 6, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended June 30, 2025. "This
More news about: Novavax, Inc.
Jul 30, 2025, 08:00 ET Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025
GAITHERSBURG, Md., July 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time
More news about: Novavax, Inc.
Jul 24, 2025, 08:00 ET Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based
More news about: Novavax, Inc.